Gastrointestinal Cancer Metastatic
9
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
MAESTRO Study: Metabolic Imaging to Improve Patient-Specific Therapy Outcomes
Electronic Patient Reported Outcomes in Patients With Gastrointestinal Cancers
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Drug Sensitivity Screening for Gastrointestinal Cancer
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer